Critical State of Remission-Recurrence of Ulcerative Colitis

Research on the Biological Basis of Disease-Syndrome-Formula in the Critical State of Remission-Recurrence of Ulcerative Colitis (Joint Application A)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06694883

Acronym

CSRRUC

Enrollment

100

Registered

2024-11-19

Start date

2024-09-19

Completion date

2025-05-31

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

This study will recruit 100 patients with ulcerative colitis in remission for a 6-month non intervention follow-up observation. During the study, their conditions will be recorded truthfully, including general information, disease-related symptoms and signs, inflammatory bowel disease questionnaire, anxiety self-assessment scale, depression self-assessment scale, etc., every month. Collect blood, urine, and stool samples from patients every month for examination. Follow up for each subject until their condition recurs.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients who meet the criteria based on the clinical characteristics of ulcerative colitis patients in the remission recurrence critical state, combined with clinical symptoms, are diagnosed with ulcerative colitis through imaging, endoscopy, laboratory, and histopathological examinations; * Patients with comprehensive laboratory testing indicators.

Exclusion criteria

* Patients with incomplete case information records; * Patients who have not completed serological tests; * Complications including intestinal obstruction, intestinal perforation, toxic megacolon, and severe local stenosis; * Diagnosed or suspected patients with coexisting uncertain colitis, infectious or ischemic colitis; * Patients with coexisting local or systemic infections, any malignant diseases, or autoimmune diseases; * Merge primary diseases such as respiratory, circulatory, neurological, endocrine, and hematological disorders; * Individuals at risk of developing cancer; * regnant or lactating women.

Design outcomes

Primary

Measure	Time frame	Description
The recurrence rate of patients	The recurrence status of patients will be recorded during the 6-month follow-up period, and the recurrence rate will be calculated after all patients have completed the follow-up. It will take about 1 year to complete the entire process	The recurrence rate of 100 follow-up patients was counted at the end of the follow-up period

Countries

China

Contacts

Primary ContactDanyan Li, Doctor

danyan20121027@163.com15811263607

Backup ContactYun Ma, Master

mayun331@163.com13681009659

Outcome results